3 Things You Need to Know
On one hand…
 In April, the company
said many short attacks
were, “exceptionally—
and likely
intentionally—
misleading.”
...
 Organovo was expected to finish functional validation
of its 3-D liver assays in March, and have them to Key
Opinion Lea...
 Organovo has not provided a timeline for when KOL
findings will be released.
 However, since the liver assays will laun...
Investing in cutting-edge companies like Organovo is
fun, but such speculative companies alone shouldn’t
dominate your por...
Organovo: 3 Things to Know
Organovo: 3 Things to Know
Organovo: 3 Things to Know
Upcoming SlideShare
Loading in …5
×

Organovo: 3 Things to Know

4,178 views

Published on

Published in: Economy & Finance, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
4,178
On SlideShare
0
From Embeds
0
Number of Embeds
3,700
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • Third paragraph http://ir.organovo.com/news/press-releases/press-releases-details/2014/Organovo-Comments-on-Misleading-and-Inaccurate-Reports/default.aspx
    Second question http://www.organovo.com/investors/frequently-asked-questions
  • Organovo: 3 Things to Know

    1. 1. 3 Things You Need to Know
    2. 2. On one hand…  In April, the company said many short attacks were, “exceptionally— and likely intentionally— misleading.”  The company filed a libel lawsuit against one research firm putting out short attacks.  While the facts being used might be in question, there’s no doubt this is a speculative company.  Essentially no product revenue has ever been created.  Management has had a number of dilutive offerings. On the other…
    3. 3.  Organovo was expected to finish functional validation of its 3-D liver assays in March, and have them to Key Opinion Leaders (KOLs) by April.  The company reached both of those goals by late January.  Demand has been strong enough for these assays that the company is conducting liver toxicity tests for selected customers ahead of the product’s December 2014 launch.
    4. 4.  Organovo has not provided a timeline for when KOL findings will be released.  However, since the liver assays will launch prior to 2015, KOL opinions will likely be released before that time.  Investors likely won’t get a chance to see revenue numbers before mid-2015 earnings are released, so these KOL opinions will have a major impact on the company’s stock…and the investment thesis for shareholders.
    5. 5. Investing in cutting-edge companies like Organovo is fun, but such speculative companies alone shouldn’t dominate your portfolio. To get a list of solid, steady, dividend payers, check out our special free report: Top Dividend Stocks for the Next Decade

    ×